Basic Information
| LncRNA/CircRNA Name | RP11-732M18.3 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, in vitro knockdown |
| Sample | Human U87MG, A172, and U251 glioma cell lines, Frozen and normal glioma tissues |
| Expression Pattern | up-regulated |
| Function Description | the newly discovered noncoding RNA RP11-732M18.3, which is highly overexpressed in glioma cells and interacts with 14-3-3?/? to promote glioma growth, acting as an oncogene. Overexpression of lncRNA RP11-732 M18.3 was associated with the proliferation of glioma cells and tumor growth in vitro and in vivo. Remarkably, lncRNA RP11-732M18.3 promoted cell proliferation and G1/S cell cycle transition. lncRNA RP11-732M18.3 is predominately localized in the cytoplasm. Mechanistically, the interaction of lncRNA RP11- 732M18.3 with 14-3-3?/? increases the degradation of the p21 protein. lncRNA RP11-732M18.3 promoted the recruitment of ubiquitin-conjugating enzyme E2 E1 to 14-3-3?/? and the binding of 14-3-3?/? with ubiquitin-conjugating enzyme E2 E1 (UBE2E1) promoted the degradation of p21. |
| Pubmed ID | 31202814 |
| Year | 2019 |
| Title | The binding of lncRNA RP11-732M18.3 with 14-3-3 ?/? accelerates p21 degradation and promotes glioma growth |
External Links
| Links for RP11-732M18.3 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |